Surface Modified Polymers for Tissue Engineering

用于组织工程的表面改性聚合物

• 批准号: 6645726
• 负责人: ROBERT S WARD
• 金额: $ 10万
• 依托单位: POLYMER TECHNOLOGY GROUP, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-11 至 2003-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6645726
• 关键词: apoptosis; biomaterial development /preparation; cell differentiation; cell migration; cell proliferation; cytology; heparin; hydropathy; polymers; polyurethanes; spectrometry; surface plasmon resonance; surface property; tissue engineering; tissue support frame

DESCRIPTION (provided by applicant): The goal of this proposal is to determine the feasibility of optimizing polymeric tissue scaffolds using novel Surface Modifying Endgroups (SME). Biostable segmented polyurethane's (SPU) will be synthesized with five different SMEs and tested by in vitro cell culture. These surface-modified SPUs will include three 'passive' SMEs with decreasing hydrophobicity; fluorocarbon, silicone and polyethyleneoxide (PEO), an SME that binds heparin, and a PEO SME that covalently bind peptides. The base polymer will be Biospan SPU, a widely used cardiovascular biomaterial with a comprehensive FDA Master File. Surfaces will be characterized by Sum Frequency Generation (SFG) vibrational spectroscopy, Atomic Force Microscopy (AFM), and Contact Angle Goniometry. Tensile properties will be measured on an Instron. Phase I will determine cellular response to water-extracted films of the materials. In vitro studies will include: cell adhesion force, cell migration, cell proliferation, cell apoptosis, and cell differentiation. In Phase II, promising materials will be used to manufacture a small-diameter, microporous vascular graft for in vivo testing, using fabrication methods already developed by the PI for two existing clinical SPU vascular grafts. In Phase II SMEs will be coupled to a base polymer that biodegrades to liquid by-product: a novel family of polyethyleneoxide block copolymers with tailorable degradation rate.

描述（由申请人提供）： 该提案的目标是确定使用新型表面修饰端基（SME）优化聚合物组织支架的可行性。生物稳定的嵌段聚氨酯 (SPU) 将由五种不同的 SME 合成，并通过体外细胞培养进行测试。这些表面改性 SPU 将包括三个疏水性降低的“被动”SME；碳氟化合物、有机硅和聚环氧乙烷 (PEO)，一种结合肝素的 SME，以及一种共价结合肽的 PEO SME。基础聚合物将是 Biospan SPU，这是一种广泛使用的心血管生物材料，具有全面的 FDA 主文件。表面将通过和频生成 (SFG) 振动光谱、原子力显微镜 (AFM) 和接触角测角法进行表征。拉伸性能将在 Instron 上测量。第一阶段将确定细胞对材料的水提取膜的反应。体外研究将包括：细胞粘附力、细胞迁移、细胞增殖、细胞凋亡和细胞分化。在第二阶段，将使用有前途的材料来制造用于体内测试的小直径、微孔血管移植物，使用PI已经为两个现有的临床SPU血管移植物开发的制造方法。在第二阶段，SME 将与可生物降解为液体副产品的基础聚合物偶联：具有可定制降解速率的新型聚环氧乙烷嵌段共聚物系列。